Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US-10206877-B2 · Feb 19, 2019 · US
US10875846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10875846-B2 |
| Application number | US-202016741276-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 13, 2020 |
| Priority date | Jan 15, 2019 |
| Publication date | Dec 29, 2020 |
| Grant date | Dec 29, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1).
Opening claim text (preview).
What is claimed is: 1. A process for the preparation of Tezacaftor (1): comprising: (i) cyclizing, in the presence of a catalyst (C3) and a solvent (S7), a compound of Formula (3): or a salt thereof, wherein R 1 is H or P 1 ; R 2 is H or P 2 ; and P 1 and P 2 are hydroxyl protecting groups that may be the same or different; to provide either Tezacaftor (1) when each of R 1 and R 2 is H, or, a compound of Formula (2): or a salt thereof, wherein R 1′ is H or P 1 ; R 2′ is H or P 2 ; R 1′ and R 2′ are not both H; and P 1 and P 2 are hydroxyl protecting groups that may be the same or different; and (ii) when either or both of R 1 and R 2 in the compound of Formula (3) is a hydroxyl protecting group P 1 or P 2 , deprotecting the compound of Formula (2) in the presence of a solvent (S8) to provide Tezacaftor (1). 2. The process of claim 1 , wherein the catalyst (C3) is palladium(II) chloride. 3. The process of claim 1 , wherein R 1 is P 1 ; R 2 is P 2 ; and P 1 and P 2 are CR a R b R c groups that may be the same or different, wherein R a , R b and R c are independently selected from the group consisting of H, an unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted alkyl group having 1 to 10 carbon atoms in the alkyl portion, an unsubstituted aryl group having 6 to 14 ring carbon atoms, and a substituted aryl group having 6 to 14 ring carbon atoms; wherein at least one of R a , R b and R c is a substituted or unsubstituted aryl group having 6 to 14 ring carbon atoms. 4. The process of claim 3 , wherein each of P 1 and P 2 is a benzyl group. 5. The process of claim 3 , wherein deprotecting the compound of Formula (2) comprises hydrogenation in the presence of a catalyst (C4) that is palladium on carbon. 6. The process of claim 1 , wherein the compound of Formula (3), or a salt thereof, is prepared by reacting, in the presence of a catalyst (C2), a solvent (S6) and a base (B2), a compound of Formula (5): or a salt thereof, wherein X is halide or trifluoromethanesulfonate; R 1 is H or P 1 ; and P 1 is a hydroxyl protecting group. with a compound of Formula (4): wherein R 2 is H or P 2 ; and P 2 is a hydroxyl protecting group. 7. The process of claim 6 , wherein the catalyst (C2) is bis(benzonitrile)palladium(II) dichloride. 8. The process of claim 7 , wherein the catalyst (C2) is used in combination with a phosphine ligand (L) that is 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl. 9. The process of claim 6 , wherein the compound of Formula (5), or a salt thereof, is prepared by reacting, in the presence of a solvent (S5) and an activator (Ac2), a compound of Formula (7): wherein X is halide or trifluoromethanesulfonate; with a compound of Formula (6): wherein R 1 is H or P 1 ; and P 1 is a hydroxyl protecting group. 10. The process of claim 9 , wherein the activator (Ac2) is a Lewis acid of the Formula MY n , wherein M is a metal selected from the group consisting of aluminum, bismuth, copper, indium, scandium, ytterbium and zinc; Y is trifluoromethanesulfonate or halide; and n is the valency of metal M. 11. The process of claim 10 , wherein the activator (Ac2) is copper(II) triflate. 12. The process of claim 9 , wherein the compound of Formula (7), or a salt thereof, is prepared by a process comprising: (i) reacting, in the presence of a solvent (S1), a compound of Formula (12): wherein X is halide or trifluoromethanesulfonate; with a compound P a -LG 1 , wherein P a is an amino protecting group; and LG 1 is a leaving group; to afford a compound of Formula (11): (ii) reducing, in the presence of a solvent (S2) and a reductant, the compound of Formula (11) to afford a compound of Formula (10): or a salt thereof, wherein X is halide or trifluoromethanesulfonate; and P a is an amino protecting group; (iii) reacting, in the presence of a solvent (S3), a compound of Formula (10) and a compound of Formula (9): wherein G is OH or LG 2 ; and LG 2 is a leaving group, to afford a compound of Formula (8): wherein X is halide or trifluoromethanesulfonate; and P a is an amino protecting group; and (iv) deprotecting the compound of Formula (8) to provide the compound of Formula (7). 13. The process of claim 12 , wherein X is bromide. 14. The process of claim 13 , wherein P a is a tert-butoxycarbonyl group. 15. A compound of Formula (3): or a salt thereof, wherein R 1 is H or P 1 ; R 2 is H or P 2 ; and P 1 and P 2 are hydroxyl protecting groups that may be the same or different. 16. The compound of claim 15 , wherein R 1 is P 1 ; R 2 is P 2 ; and P 1 and P 2 are CR a R b R c groups that may be the same or different, wherein R a , R b and R c are independently selected from the group consisting of H, an unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted alkyl group having 1 to 10 carbon atoms in the alkyl portion, an unsubstituted aryl group having 6 to 14 ring carbon atoms, and a substituted aryl group having 6 to 14 ring carbon atoms; wherein at least one of R a , R b and R c is a substituted or unsubstituted aryl group having 6 to 14 ring carbon atoms. 17. The compound of claim 16 , wherein R 1 and R 2 are both benzyl. 18. A compound of Formula (10): wherein X is s halide or trifluoromethanesulfonate; and P a is an amino protecting group selected from the group consisting of substituted or unsubstituted alkyloxycarbonyl groups; substituted or unsubstituted arylalkyloxycarbonyl groups; substituted or unsubstituted alkylcarbonyl groups; and substituted or unsubstituted arylalkylcarbonyl groups. 19. The compound of claim 18 , wherein X is bromide. 20. The compound of claim 19 , wherein P a is a tert-butoxycarbonyl group.
Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups · CPC title
from amines with formation of carbamate groups · CPC title
to a carbon atom of a non-condensed six-membered aromatic ring · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.